186 related articles for article (PubMed ID: 38256193)
1. Evaluation of the Therapeutic Effects of Harmine on Anaplastic Thyroid Cancer Cells.
Baldini E; Cardarelli S; Campese AF; Lori E; Fallahi P; Virili C; Forte F; Pironi D; Di Matteo FM; Palumbo P; Costanzo ML; D'Andrea V; Centanni M; Sorrenti S; Antonelli A; Ulisse S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256193
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines.
Shi XZ; Zhao S; Wang Y; Wang MY; Su SW; Wu YZ; Xiong C
Drug Des Devel Ther; 2023; 17():1889-1906. PubMed ID: 37397788
[TBL] [Abstract][Full Text] [Related]
3. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma.
Gao H; Wang W; Li Q
Cancer Biol Ther; 2022 Dec; 23(1):369-377. PubMed ID: 35491899
[TBL] [Abstract][Full Text] [Related]
4. Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1.
Nafie E; Lolarga J; Lam B; Guo J; Abdollahzadeh E; Rodriguez S; Glackin C; Liu J
PLoS One; 2021; 16(2):e0247652. PubMed ID: 33626096
[TBL] [Abstract][Full Text] [Related]
5. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.
Yochum ZA; Cades J; Mazzacurati L; Neumann NM; Khetarpal SK; Chatterjee S; Wang H; Attar MA; Huang EH; Chatley SN; Nugent K; Somasundaram A; Engh JA; Ewald AJ; Cho YJ; Rudin CM; Tran PT; Burns TF
Mol Cancer Res; 2017 Dec; 15(12):1764-1776. PubMed ID: 28851812
[TBL] [Abstract][Full Text] [Related]
6. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
7. Ellagic acid inhibits cell proliferation, migration, and invasion of anaplastic thyroid cancer cells via the Wnt/β-catenin and PI3K/Akt pathways.
Meng X; Cui Z; Shi H; Ma X; Li W; Liu X; Jiang Y
Acta Biochim Pol; 2023 Feb; 70(1):109-115. PubMed ID: 36773307
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells.
Kocdor MA; Cengiz H; Ates H; Kocdor H
Anticancer Agents Med Chem; 2019; 19(15):1887-1898. PubMed ID: 31584382
[TBL] [Abstract][Full Text] [Related]
9. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
Che HY; Guo HY; Si XW; You QY; Lou WY
Tumour Biol; 2014 Sep; 35(9):8659-64. PubMed ID: 24867098
[TBL] [Abstract][Full Text] [Related]
10. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
11. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study.
Durai L; Ravindran S; Arvind K; Karunagaran D; Vijayalakshmi R
Mol Biol Rep; 2021 Nov; 48(11):7443-7456. PubMed ID: 34716862
[TBL] [Abstract][Full Text] [Related]
13. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma.
Wang Z; Qiu X; Zhang H; Li W
J Biochem Mol Toxicol; 2020 May; 34(5):e22469. PubMed ID: 32173973
[TBL] [Abstract][Full Text] [Related]
14. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
15. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
[TBL] [Abstract][Full Text] [Related]
16. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
18. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
19. Blocking CDK7-Mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Doolittle WKL; Zhao L; Cheng SY
Thyroid; 2022 Aug; 32(8):937-948. PubMed ID: 35822558
[No Abstract] [Full Text] [Related]
20. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
